Fibromuscular dysplasia (FMD), a disease that primarily affects young to middle-aged women, is characterized by the proliferation of connective tissue and muscle fibers within the arterial vessel walls.

Epidemiology


Etiology


Pathophysiology


Fibromuscular dysplasia (FMD) is an idiopathic, non-inflammatory, non-atherosclerotic, developmental condition that primarily affects small and medium-sized muscular arteries.

  • FMD results in ischemia by one or more of the following mechanisms:
    • Stenosis
    • Formation of saccular aneurysms → aneurysmal rupture
    • Arterial dissection → arterial occlusion
  • Renal artery stenosis → ↓ renal perfusion → compensatory activation of the renin–angiotensin–aldosterone system → secondary hypertension
  • Disease localization
    • Renal artery (renal FMD; ∼ 75–80% of cases)
    • Carotid and vertebral artery involvement (extracranial cerebrovascular FMD; ∼ 65–75% of cases and often bilateral)

Clinical features


  • Renal Artery Involvement (Most common):
    • Severe, refractory, or new-onset HTN in a young pt. c
    • Abdominal bruit (periumbilical/flank).
  • Cerebrovascular Involvement (Carotid/Vertebral):
    • Headache, pulsatile tinnitus.
    • TIA, stroke, or amaurosis fugax.
    • Subauricular/cervical bruit.
  • Other Arteries (Mesenteric, Iliac): Atypical claudication, mesenteric ischemia (rare).

Diagnostics


  • Best initial tests for renal FMD: duplex ultrasonography and/or CT angiography
    • Common finding: “string of beads” sign
  • Key Labs: ↑ Plasma Renin Activity (PRA), ↑ Aldosterone (Secondary hyperaldosteronism due to renal ischemia). Normal aldosterone/renin ratio (&lt 20).
  • Differential diagnostics

FeatureFibromuscular Dysplasia (FMD)Atherosclerosis
PatientYoung FemalesElderly Males
Risk FactorsSmoking, Female sex, GeneticsSmoking, DM, HTN, Hyperlipidemia
LocationDistal 2/3 of renal arteryProximal 1/3 (Ostial)
Imaging”String of beads”Focal narrowing
PathologyMedial fibroplasiaPlaque / Foam cells
TreatmentAngioplasty (PTA)Medical Mgmt (ACEi/ARBs*)

Treatment